Literature DB >> 9350293

Interleukin-10 response abnormalities in systemic lupus erythematosus.

A E Mongan1, S Ramdahin, R J Warrington.   

Abstract

It has been previously reported that the production of interleukin-6 (IL-6) is often enhanced in systemic lupus erythematosus (SLE). The authors examined the secretion of IL-6, tumour necrosis factor-alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor, IL-1 alpha and IL-4 by B cells and monocytes from lupus patients and compared this to the production in normal controls and in rheumatoid arthritis patients. IL-6 production was increased an average of 3.4-fold compared to that in normal subjects and 8.4-fold compared to rheumatoid arthritis patients. In SLE, a strongly positive correlation was found between the levels of IL-6 and TNF-alpha (R = 0.8987, P = 0.002). Since production of both IL-6 and TNF-alpha is regulated by IL-10, the enhancement of the production of these cytokines could reflect a defect in either IL-10 production or responsiveness. However, spontaneous production of IL-10 was enhanced in cultures of B cells and monocytes from lupus patients, compared to normal controls, the levels being increased 3.1- to 6-fold for monocytes and B cells, respectively. The finding of increased secretion of these cytokines implies an abnormality in IL-10-mediated suppression in SLE. To assess this possibility, the authors examined recombinant human IL-10-mediated suppression of IL-6 production by monocytes and B cells from lupus patients, compared to normal controls, and found that whereas IL-10 caused a concentration-dependent suppression of IL-6 production in normal B cells and monocytes, this suppression was deficient in B cells and monocytes from lupus patients. In SLE, it therefore appears that there may be an intrinsic defect in IL-10-induced suppression of cytokine synthesis. This could explain the increased levels of IL-10 and IL-6 found in this condition, and may also be responsible for the characteristic polyclonal B-cell activation that is seen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350293     DOI: 10.1046/j.1365-3083.1997.d01-140.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  12 in total

1.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Biomarkers of lupus nephritis determined by serial urine proteomics.

Authors:  Xiaolan Zhang; Ming Jin; Haifeng Wu; Tibor Nadasdy; Gyongyi Nadasdy; Nathan Harris; Kari Green-Church; Haikady Nagaraja; Daniel J Birmingham; Chack-Yung Yu; Lee A Hebert; Brad H Rovin
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

3.  Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE.

Authors:  J Rönnelid; A Tejde; L Mathsson; K Nilsson-Ekdahl; B Nilsson
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

4.  The association of -627 interleukin-10 promoter polymorphism in Chinese patients with systemic lupus erythematosus.

Authors:  Po-Wen Lin; Chung-Ming Huang; Chiu-Ching Huang; Chang-Hai Tsai; Jeffrey J P Tsai; Chin-Ping Chang; Fuu-Jen Tsai
Journal:  Clin Rheumatol       Date:  2006-07-07       Impact factor: 2.980

5.  Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies.

Authors:  L Mathsson; E Ahlin; C Sjöwall; T Skogh; J Rönnelid
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

6.  IL-10 stimulates production of platelet-activating factor by monocytes of patients with active systemic lupus erythematosus (SLE).

Authors:  B Bussolati; C Rollino; F Mariano; F Quarello; G Camussi
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

7.  Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).

Authors:  A Csiszár; G Nagy; P Gergely; T Pozsonyi; E Pócsik
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

Review 8.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

9.  Cytokine-induced monocyte characteristics in SLE.

Authors:  Zhe Zhang; Kelly Maurer; Juan C Perin; Li Song; Kathleen E Sullivan
Journal:  J Biomed Biotechnol       Date:  2010-06-24

Review 10.  Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms.

Authors:  Xiaoyu Hu; Soumya D Chakravarty; Lionel B Ivashkiv
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.